Stocktoria

Neuronetics, Inc. STIM

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
4/9
Piotroski F — financial health
-10.42
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$149.2M-$39.0M$72.3M$22.4M
2024$74.9M-$43.7M$54.2M$31.8M
2023$71.3M-$30.2M$51.7M$34.2M
2022$65.2M-$37.2M$49.7M$57.1M
2021$55.3M-$31.2M$43.7M$85.2M
2020$49.2M-$27.5M$37.7M$25.5M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Madryn Asset Management, LP10% owner2026-06-15J4,634
Madryn Asset Management, LP10% owner2026-06-15J34,932
Amin Avinashdirector2026-06-15J34,932
Amin Avinashdirector2026-06-15J2,934
Amin Avinashdirector2026-06-15J4,634
Madryn Asset Management, LP10% owner2026-06-15J2,934
Madryn Asset Management, LP10% owner2026-05-28J3,271
Madryn Asset Management, LP10% owner2026-05-28J24,658

Why these scores methodology →

Piotroski F-score: 4/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -10.42 (distress)

  • Working capital / assets 0.219
  • Retained earnings / assets -3.241
  • EBIT / assets -0.222
  • Equity / liabilities 0.194

Source: SEC EDGAR filings · CIK 0001227636 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.